PDF factsheet
      Z

antithrombotics in venous thrombosis for patients with cancer, clinical trials results

edoxaban versus dalteparin
Hokusai-VTE Cancer, 2017
NCT02073682
low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily. Treatment was given for atleast 6 months and up to 12 months.
versus
subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily
patients with cancer who had acute symptomatic or incidental venous thromboembolismopen label
extended dalteparin versus standard treatment
CLOT (Lee), 2003
Dalteparin 200 IU/kg daily for 1 month followed by 150 IU/kg daily for 5 months
versus
Dalteparin 200 IU/kg daily for 5-7 days followed by wafarin or acecumarol (target INR 2-3) for 6 months
patients with active cancer and with DVT or pulmonary embolism or both, and ECOG 1 or 2outcome assessment blinded
Follow-up duration: 6 months
extended enoxaparin versus standard treatment
Cesarone, 2003
Enoxaparin 100UL/Kg twice daily for 3 months
versus
coumadin (target INR 3) for 3 months.
patients with cancer with DVTNA
Follow-up duration: 3 months
Deitcher, 2006
Enoxaparin 1mg/kg twice daily for 5 days followed by 1-1.5mg/kg daily for 175 days
versus
Enoxaparin 1mg/kg twice daily for 5 days followed by warfarin (target INR 2-3) for a total of 180 days
patients with cancer with DVT and/or PEnone
Follow-up duration: 12 months
Meyer, 2002
Enoxaparin 1.5 mg/kg daily for 3 monthsmag
versus
Enoxaparin 1.5 mg/kg daily for 4 days followed by warfarin (target INR 2-3) for 3 months
patients with cancer (solid or hematological; active or in remission but on treatment); with pulmonary embolism and/or DVT and a minimum life expectancy of 3 monthsoutcome assessment blinded
Follow-up duration: 3 months
extended nadroparin versus standard treatment
Lopez Beret, 2001
Nadroparin 1.025 antiXa IU/10Kg twice daily after aadroparin 1.025AXa IU/10Kg twice daily for 3 days. After 3 months, nadroparin was switched to once daily
versus
acenocoumarol (target INR 2-3) for 3-6 months after nadroparin 1.025AXa IU/10Kg twice daily for 3 days
patients with known malignancy treated for symptomatic DVT of the lower limboutcome assessment blinded
Follow-up duration: 12 months
extended tinzaparin versus standard treatment
Hull, 2006
Tinzaparin 175 antiXa/kg SQ daily for 12 weeks
versus
UFH for 5 days followed by vitamin K antagonist (target INR 2-3) for 12 weeks
patients with cancer (solid or hematological) with proximal DVT with or without PE and with a minimum life expectancy of 3 months imagoutcome assessment blinded
Follow-up duration: 3 months
idraparinux versus standard treatment
Van Gogh (subgroup), 2011
once-weekly subcutaneous injection of idraparinux (2.5 mg) for 6 months
versus
standard treatment for three months (8%) or six months (92%)
non-active and active cancer patients with deep venous thrombosis and without pulmonary embolism, included in the Van Gogh DVT clinical trial
Follow-up duration: 6 months
rivaroxaban versus dalteparin
SELECT D, 2018
rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
versus
dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lowerextremity proximal deep vein thrombosis (DVT)open-design
rivaroxaban versus enoxaparin
EINSTEIN (subgroup), 2014
rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily
versus
(enoxaparin1·0 mg/kg twice daily and warfarin or acenocoumarol; international normalised ratio 2·0–3·0
subgroup analysis of patients with active cancer (either at baseline or diagnosed during the study) who were enrolled in the EINSTEIN-DVT and EINSTEIN-PE trials
tinzaparin versus dalteparin
Wells (subgroup), 2005
Tinzaparin 175 IU/kg SQ daily (warfarin started simultaneously and continued for 90 days)
versus
dalteparin 200 IU/kg daily for at least 5 days ((warfarin started simultaneously and continued for 90 days)
study subgroup of patients with cancer treated for upper or lower extremity DVT or PE in the outpatient settingoutcome assessment blinded
Follow-up duration: 3 months
ximelagatran versus placebo
Schulman (subgroup), 2003
extended treatment with Ximelagatran 24mg twice daily after initial anticoagulant treatment for 6 months
versus
placebo (initial anticoagulant treatment for 6 months)
study subgroup of patients with active cancer in the previous 5 years treated for DVT or pulmonary embolism for 6 months without recurrencesingle blind and outcome ass.
Follow-up duration: 18 months

  Options


in first

in second

  Filter